We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+5.25%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$34.6M
Cap. Flow
+$36.2M
Cap. Flow %
10.1%
Top 10 Hldgs %
49.91%
Holding
70
New
7
Increased
17
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.4M
2
HRMY icon
Harmony Biosciences
HRMY
+$13.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.9M
4
VERA icon
Vera Therapeutics
VERA
+$5.57M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$5.45M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$35.8M
2
TVTX icon
Travere Therapeutics
TVTX
+$5.06M
3
ILMN icon
Illumina
ILMN
+$4.21M
4
QURE icon
uniQure
QURE
+$3.21M
5
DYN icon
Dyne Therapeutics
DYN
+$2.69M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$6B
$912K 0.25%
25,500
– –
NTLA icon
52
Intellia Therapeutics
NTLA
$1.84B
$894K 0.25%
24,000
– –
ACET icon
53
Adicet Bio
ACET
$84.3M
$890K 0.25%
9,669
– –
HCM icon
54
HUTCHMED
HCM
$2.16B
$885K 0.25%
68,000
– –
BEAM icon
55
Beam Therapeutics
BEAM
$3.15B
$718K 0.2%
23,500
– –
INSM icon
56
Insmed
INSM
$26.5B
$682K 0.19%
40,100
– –
IRWD icon
57
Ironwood Pharmaceuticals
IRWD
$701M
$631K 0.18%
60,000
– –
VTYX
58
DELISTED
Ventyx Biosciences
VTYX
$501K 0.14%
+15,000
New +$583K
BCRX icon
59
BioCryst Pharmaceuticals
BCRX
$2.52B
$475K 0.13%
57,000
– –
ARVN icon
60
Arvinas
ARVN
$604M
$464K 0.13%
17,000
– –
IOVA icon
61
Iovance Biotherapeutics
IOVA
$3.74B
$342K 0.1%
56,000
– –
IDYA icon
62
IDEAYA Biosciences
IDYA
$4.03B
$261K 0.07%
19,000
-90,000
-83% -$1.5M
RLMD icon
63
Relmada Therapeutics
RLMD
$482M
$22.5K 0.01%
10,000
– –
ALLO icon
64
Allogene Therapeutics
ALLO
$722M
– –
-50,000
Closed -$314K
FATE icon
65
Fate Therapeutics
FATE
$304M
– –
-46,000
Closed -$464K
FULC icon
66
Fulcrum Therapeutics
FULC
$294M
– –
-193,741
Closed -$1.41M
CNCE
67
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-200,800
Closed -$1.17M
ALBO
68
DELISTED
Albireo Pharma Inc
ALBO
– –
-38,000
Closed -$820K
HZNP
69
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-314,973
Closed -$35.8M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2023 Portfolio in Review

As of Q1 2023, International Biotechnology Trust held 70 positions worth $358M, up 11% from $324M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

International Biotechnology Trust deployed $36.2M of net new capital in Q1 2023, opening 7 new positions and adding to 17 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 33,000 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $5.06M trimmed.

  • International Biotechnology Trust's largest Q1 2023 buy was Vertex Pharmaceuticals: 33,000 shares worth $10.4M.
  • International Biotechnology Trust added most to Amgen in Q1 2023, an estimated $18.4M increase.
  • International Biotechnology Trust's biggest Q1 2023 reduction was Travere Therapeutics, cutting an estimated $5.06M.
  • International Biotechnology Trust fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $35.8M.
  • International Biotechnology Trust's ten largest holdings make up 50% of its $358M portfolio in Q1 2023.
  • International Biotechnology Trust opened 7 new positions and closed 6 in Q1 2023.
  • International Biotechnology Trust's portfolio value rose 11% quarter-over-quarter to $358M.

Based on International Biotechnology Trust's 13F filing for Q1 2023, filed 18 May 2023.